Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Level V
Where this comes from
- Record sourced from PubMed, PMID 20622048.
- Also identified by DOI 10.1158/1078-0432.CCR-10-1496 and PMC identifier 2932783.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway increases arsenic trioxide (ATO)-dependent cytotoxicity of chronic lymphocytic leukemia (CLL) cells, whereas it has no significant effects on normal lymphocytes. Combinations of ATO with small molecules that target PI3K and/or Akt may provide a novel approach for the treatment of CLL.
Medical subject headings
- Apoptosis
- Arsenicals
- JNK Mitogen-Activated Protein Kinases
- Oxides
- PTEN Phosphohydrolase
- Signal Transduction